Skip to main content
Fig. 4 | The Journal of Headache and Pain

Fig. 4

From: Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany

Fig. 4

Global impression scale in migraine patients after 3 months of erenumab treatment – medical chart review (N = 542); EM = episodic migraine; CM = chronic migraine; Clinical global impression scale of improvement was defined by responses of very much improved, clearly improved, somewhat improved, no change, clearly deteriorated and very much deteriorated

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us